Lyell Immunopharma, Inc. — Director's Dealing 2025

Mar 25, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2025-03-21

Reporting Person: Ramachandra Sumant (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-21	Common Stock	P	200000	$0.5761	Acquired	200000	Indirect

Footnotes

F1: The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.5487 to $0.5879, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range.

F2: Shares held by the Sumant Ramachandra Rev Trust DTD 01/24/12. The Reporting Person is grantor and trustee of the Sumant Ramachandra Rev Trust DTD 01/24/12.